Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Genomics is transforming the future of modern medicine and treatment modalities across specialties
The plant will have installed production capacity of 3,120 MT/month
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
The supply of these goods is set to commence within the first quarter of FY26
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
Strengthening capabilities in Peptide Therapeutics and CDMO services
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
Subscribe To Our Newsletter & Stay Updated
